Liquid Biopsy in Ovarian Cancer: Advantages and Limitations for Prognosis and Diagnosis

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2023 Aug 10

PMID 37561363

Authors

Farzaneh Karimi

Omid Azadbakht

Ali Veisi

Mohammad Sabaghan

Maryam Owjfard

Ebrahim Kharazinejad

Negar Dinarvand

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is a highly fatal gynecologic malignancy, often diagnosed at an advanced stage which presents significant challenges for disease management. The clinical application of conventional tissue biopsy methods and serological biomarkers has limitations for the diagnosis and prognosis of OC patients. Liquid biopsy is a novel sampling method that involves analyzing distinctive tumor elements secreted into the peripheral blood. Growing evidence suggests that liquid biopsy methods such as circulating tumor cells, cell-free RNA, circulating tumor DNA, exosomes, and tumor-educated platelets may improve early prognosis and diagnosis of OC, leading to enhanced therapeutic management of the disease. This study reviewed the evidence demonstrating the utility of liquid biopsy components in OC prognosis and diagnosis, and evaluated the current advantages and limitations of these methods. Additionally, the existing obstacles and crucial topics for future studies utilizing liquid biopsy in OC patients were discussed.

Citing Articles

Gynecologic Cancer Screening and Prevention: State of the Science and Practice.

Tran C, Diaz-Ayllon H, Abulez D, Chinta S, Williams-Brown M, Desravines N Curr Treat Options Oncol. 2025; .

PMID: 40014217 DOI: 10.1007/s11864-025-01301-z.

Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.

The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.

Barbosa J, Antoniosi Filho N Metabolomics. 2024; 20(5):113.

PMID: 39375265 DOI: 10.1007/s11306-024-02180-5.

USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.

Chen J, Shan W, Jia Q, Chen Y, Jiang W, Tian Y Oncogene. 2024; 43(43):3170-3183.

PMID: 39256572 DOI: 10.1038/s41388-024-03151-9.

Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.

Gromek P, Senkowska Z, Pluciennik E, Pasieka Z, Zhao L, Gielecinska A World J Methodol. 2024; 14(2):92982.

PMID: 38983668 PMC: 11229876. DOI: 10.5662/wjm.v14.i2.92982.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Brown Y, Hua S, Tanwar P . Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology. Matrix Biol. 2023; 118:16-46. DOI: 10.1016/j.matbio.2023.02.004. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Kobel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks C . Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. Int J Gynecol Pathol. 2018; 38(4):353-362. PMC: 6291360. DOI: 10.1097/PGP.0000000000000530. View

Sun Y, Xu J, Jia X . The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives. Cancer Manag Res. 2020; 12:3651-3659. PMC: 7246309. DOI: 10.2147/CMAR.S250394. View

Kurman R, Shih I . Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011; 42(7):918-31. PMC: 3148026. DOI: 10.1016/j.humpath.2011.03.003. View

Gonzalez-Martin A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M . Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25):2391-2402. DOI: 10.1056/NEJMoa1910962. View

Akter S, Rahman M, Hasan M, Akhter H, Noor P, Islam R . Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. Cells. 2022; 11(4). PMC: 8870715. DOI: 10.3390/cells11040650. View

Goldberg R, Kim S, Fazelzad R, Li X, Brown T, May T . Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2021; 164(1):212-220. DOI: 10.1016/j.ygyno.2021.10.080. View

10.

Chang L, Ni J, Zhu Y, Pang B, Graham P, Zhang H . Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics. 2019; 9(14):4130-4140. PMC: 6592165. DOI: 10.7150/thno.34692. View

11.

Sassu C, Palaia I, Boccia S, Caruso G, Perniola G, Tomao F . Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer. Int J Mol Sci. 2021; 22(24). PMC: 8707281. DOI: 10.3390/ijms222413650. View

12.

Cheung A, Chow C, To K . Latest development of liquid biopsy. J Thorac Dis. 2018; 10(Suppl 14):S1645-S1651. PMC: 6035915. DOI: 10.21037/jtd.2018.04.68. View

13.

Khan M, Vikramdeo K, Sudan S, Singh S, Wilhite A, Dasgupta S . Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Semin Cancer Biol. 2021; 77:99-109. PMC: 8665066. DOI: 10.1016/j.semcancer.2021.08.005. View

14.

Balla A, Bhak J, Biro O . The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer. Mol Cell Probes. 2022; 66:101871. DOI: 10.1016/j.mcp.2022.101871. View

15.

Wendel H, de Stanchina E, Fridman J, Malina A, Ray S, Kogan S . Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004; 428(6980):332-7. DOI: 10.1038/nature02369. View

16.

Allen T, Asad D, Amu E, Hensley M, Cores J, Vandergriff A . Circulating tumor cells exit circulation while maintaining multicellularity, augmenting metastatic potential. J Cell Sci. 2019; 132(17). PMC: 6771143. DOI: 10.1242/jcs.231563. View

17.

Alix-Panabieres C, Pantel K . Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016; 6(5):479-91. DOI: 10.1158/2159-8290.CD-15-1483. View

18.

Nguyen D, Bos P, Massague J . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9(4):274-84. DOI: 10.1038/nrc2622. View

19.

Fidler I . Cancer biology is the foundation for therapy. Cancer Biol Ther. 2005; 4(9):1036-9. DOI: 10.4161/cbt.4.9.2111. View

20.

Kuhlmann J, Wimberger P, Bankfalvi A, Keller T, Scholer S, Aktas B . ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014; 60(10):1282-9. DOI: 10.1373/clinchem.2014.224808. View